<DOC>
	<DOCNO>NCT00579111</DOCNO>
	<brief_summary>Blood disorder leukemia lymphoma hemoglobinopathy benefit receive allogeneic ( mean cell donor ) stem cell transplant . Stem cell create bone marrow . They grow different type blood cell body need , include red blood cell , white blood cell , platelet . In transplant , body 's stem cell would kill replaced stem cell donor . Usually , patient give high dos chemotherapy ( drug kill cancer cell ) prior receive stem cell transplant . However , patient older , receive several prior treatment , organ disease high risk get life-threatening treatment-related side effect high dos chemotherapy . Over past several year , doctor begin use low dos chemotherapy prepare patient stem cell transplant . A condition occur stem cell transplant donor Graft Versus Host Disease ( GVHD ) . It rare serious disorder strike person whose immune system suppress receive either blood transfusion bone marrow transplant . Symptoms may include skin rash , intestinal problem similar inflammation bowel liver dysfunction . This research study use combination lower-dose chemotherapy agent slightly different use . The medicine use study Fludarabine , Busulfan , chemotherapy medicine , Campath . Campath monoclonal antibody ( type substance produce laboratory bind cancer cell ) . It help immune system see cancer cell something need destroy . This research study help u learn use Fludarabine , Busulfan Campath prior allogeneic stem cell transplant provide treatment blood disorder decrease incidence side effect .</brief_summary>
	<brief_title>Reduced Intensity Preparative Regimen Followed Stem Cell Transplant ( FAB )</brief_title>
	<detailed_description>Allogeneic stem cell transplantation high-dose chemotherapy affords well chance cure malignant non-malignant hematological disease compare autologous transplantation , lack stem cell contamination immune mediate graft vs. leukemia effect . Unfortunately , high-dose chemotherapy allogeneic stem cell transplantation substantial treatment related mortality , particularly high old patient ( great 50 yrs age ) , co-morbidities congestive heart disease pulmonary disease . Patients pre-existing infection multiple relapse prior chemotherapy also high risk . In group , treatment related mortality may exceed 50 % , make ineligible high-dose chemotherapy allogeneic stem cell transplantation . Recently interest increase use less toxic chemotherapy protocol term submyeloablative . The intent allow partial engraftment donor immune hemopoietic system subsequent progressive replacement host 's hemopoiesis immunity . As donor immune system become establish , patient may develop full donor chimerism , without pass period prolong aplasia associate conventional conditioning regimen , less associated toxicity . Preliminary result high-risk patient show treatment relate mortality ( TRM ) 15-20 % , versus 50 % expect , overall survival rate 70-80 % 1-2 year post transplant . As might anticipate , major problem sub-ablative conditioning graft failure rate increase , publish figure 5-30 % versus 1-5 % predict fully ablated patient . The incorporation lymphodepleting antibody preliminary condition regimen may allow rejection rate diminish . Moreover , highly efficient lymphodepleting MAb MAb combination might successfully substitute part whole cytotoxic immunosuppressive drug , increase safety efficacy subablative approach stem cell transplantation . Our data use crude polyclonal mixture antibody ATG component pre-transplant conditioning reveal improvement engraftment match unrelated donor transplantation.The lymphodepleting monoclonal antibody Campath IH many property desire application , propose incorporate conditioning regimen . Since CAMPATH1H persist infusion , would expect additional anti-GvHD effector function , reduce treatment relate mortality ( TRM ) . The following preparative regimen deliver patient : 1 . Busulfan 3.2 mg/kg/day IV daily 2 day , infuse 3 hour , Day -5 Day -4 2 . Fludarabine 30mg/m2/day IV daily 4 day Day -5 D -2 3 . Campath 10 mg/day IV daily 3 day day -6 D-4 . Because CAMPATH-1H infusion provide persist level antibody transplant period , contribute anti-GvHD activity . Additional Graft vs. host disease prophylaxis consist FK506 administer Day-2 . The stem cell infuse day 0 .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Paraproteinemias</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Diagnosis myelodysplastic myeloproliferative disorder , acute myelogenous leukemia , acute lymphoblastic leukemia , chronic myelogenous leukemia , multiple myeloma , plasma cell dyscrasia , lymphoproliferative disorder ( nonHodgkin lymphoma , hairy cell leukemia , chronic lymphocytic leukemia , Hodgkin 's disease ) non malignant hematologic disease consider treatable allogeneic transplant include limit bone marrow failure syndrome , hemoglobinopathy severe immunodeficiency state . 2 . Performance status 02 Zubrod scale 3 . Ejection fraction &gt; 30 % 4 . AST/ALT bilirubin &gt; 4 time normal 5 . FEV1 great 1.0 diffusion capacity &gt; 40 % 6 . Age birth 70 year age 7 . Conditions increase treatment related mortality ( need one eligible ) : Age &gt; 35 year EF less 45 % DLCO le 50 % FEV1 5075 % predict value Diabetes mellitus Renal insufficiency , define increase serum creatinine level 1.5 time ULN decrease GFR 25 % Prior recent history systemic fungal infection 3rd great remission AML ALL More 1 year diagnosis ( CML myeloma patient ) Multiple type treatment regimen ( equal 3 ) Prior autologous allogeneic stem cell transplantation Significant Grade III IV neurologic hepatic toxicity define NCI CTC toxicity previous treatment No match sibling donor 8 . Available healthy donor without contraindication donation 5/6 6/6 related 5/6 6/6 unrelated ( molecular type DRB1 ) 9 . Patient and/or responsible person able understand sign consent 10 . For woman childbearing potential , negative pregnancy test 1 . Pregnant lactate woman woman unwilling use contraception . 2 . HIV positive patient . 3 . Uncontrolled intercurrent infection . 4 . Refractory AML ALL . 5 . Untreated blast crisis CML . 6 . Uncontrolled highgrade lymphoproliferative disease/lymphoma . 7 . Unstable angina uncompensated congestive heart failure ( Zubrod 3 great ) . 8 . Severe chronic pulmonary disease require oxygen ( Zubrod 3 great ) . 9 . Hemodialysis dependent . 10 . Active Hepatitis cirrhosis total bilirubin , SGOT , SGPT great 3 x normal . 11 . Serum creatinine &gt; 2x ULN . 12 . Unstable cerebral vascular disease recent hemorrhagic stroke ( le 6 month ) . 13 . Active CNS disease hematological disorder .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Myelodysplastic Myeloproliferative Disorders</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Plasma Cell dyscrasia</keyword>
	<keyword>Lymphoproliferative disorder</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Campath</keyword>
	<keyword>Alemtuzumab</keyword>
	<keyword>allogeneic stem cell transplant</keyword>
</DOC>